Hematological malignancies are among the most common cancers in the United States. Recent advances in molecular pathology led to the development of new therapy, such as Imatinib and Rituximab. However, clinical outcomes are still far from satisfactory in a subset of leukemias and lymphomas harboring specific mutations. Our goal is to elucidate the molecular mechanisms underlying normal and malignant hematopoiesis, while maintaining keenly translational focus. We take biochemical and molecular biological approaches and employ genetically modified mouse models. Specifically, our current research focuses on molecules/pathways relevant to hematological malignancies, such as LRF transcription factor, Notch and endocytic adopter proteins.